D03684;Denosumab;Denosumab (usan);AMG 162;IMMunoglobulin G2, anti-(huMan osteoclast differentiation factor) (huMan Monoclonal AMG162 heavy chain), disulfide with huMan Monoclonal AMG162 light chain, diMer;Denosumab (usan) USP/EP/BP;Research Grade Denosumab (DHA30301);Denosumab,Immunoglobulin G2,Nuclear factor-kappaB,NF-κB,Immunoglobulin G-2,RANKL,Inhibitor,Ranmark,inhibit,Cancer,Immunoglobulin G 2,Osteoporosis,Nuclear factor-κB
用途
Denosumab is a RANK ligand (RANKL) inhibitor approved by the U.S. FDA for the prevention and treatment of skeletal-related events in patients with bone metastases from solid tumors, and for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity. It is also used to increase bone mass in patients with osteoporosis, reducing the risk of vertebral, non-vertebral, and hip fractures in postmenopausal women.